Cochlear Overview
- Year Founded
-
1981
- Status
-
Public
- Employees
-
4,500
- Stock Symbol
-
COH
- Investments
-
16
- Share Price
-
$103.03
- (As of Friday Closing)
Cochlear General Information
Description
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2026, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.
Contact Information
Website
www.cochlear.comCorporate Office
- 1 University Avenue
- Macquarie University
- Sydney, New South Wales 2109
- Australia
Corporate Office
- 1 University Avenue
- Macquarie University
- Sydney, New South Wales 2109
- Australia
Cochlear Stock Performance
As of 13-Nov-2026, Cochlear’s stock price is $103.03. Its current market cap is $6.74B with 65.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $103.03 | $104.67 | $63.25 - $194.24 | $6.74B | 65.4M | 589K | $1.53 |
Cochlear Financials Summary
As of 30-Jun-2026, Cochlear has a trailing 12-month revenue of $1.59B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 5,517,496 | 5,517,496 | 12,743,766 | 14,281,791 |
| Revenue | 1,590,332 | 1,590,332 | 1,516,030 | 1,465,074 |
| EBITDA | 217,861 | 217,861 | 393,517 | 366,924 |
| Net Income | 99,785 | 99,785 | 251,626 | 233,825 |
| Total Assets | 1,791,286 | 1,791,286 | 1,845,259 | 1,834,825 |
| Total Debt | 146,378 | 146,378 | 153,957 | 162,889 |
Cochlear Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cochlear Comparisons
Industry
Financing
Details
Cochlear Competitors (11)
One of Cochlear’s 11 competitors is Demant, a Corporation company based in Smorum, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Demant | Corporation | Smorum, Denmark | ||||
| Boston Scientific | Corporation | Marlborough, MA | ||||
| Medtronic | Corporation | Minneapolis, MN | ||||
| Zimmer Biomet Holdings | Corporation | Warsaw, IN | ||||
| Globus Medical | Formerly VC-backed | Audubon, PA |
Cochlear Patents
Cochlear Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026229769-A1 | System and method for measuring skin flap thickness using signal absorption | Pending | 30-Apr-2025 | ||
| WO-2026220242-A1 | User directed frequency mapping | Pending | 16-Apr-2025 | ||
| WO-2026210286-A1 | Generating speech test materials with customizable linguistic characteristics | Pending | 01-Apr-2025 | ||
| WO-2026202656-A1 | Straightening mechanisms for implantable components | Pending | 27-Mar-2025 | ||
| WO-2026202655-A1 | Interactive aural language competency development | Pending | 26-Mar-2025 | G10L15/26 |
Cochlear Signals
Cochlear Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cochlear Investments & Acquisitions (16)
Cochlear’s most recent deal was a Later Stage VC with Epiminder for . The deal was made on 01-Feb-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Epiminder | 01-Feb-2025 | Later Stage VC | Monitoring Equipment | ||
| Oticon Medical (Cochlear Implant Business) | 21-May-2024 | Merger/Acquisition | Therapeutic Devices | ||
| Epiminder | 15-Mar-2022 | Later Stage VC | Monitoring Equipment | ||
| Precisis | 14-Oct-2021 | Later Stage VC | Therapeutic Devices | ||
| Seer Medical | 26-Aug-2021 | Early Stage VC | Monitoring Equipment |
Cochlear ESG
Risk Overview
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Devices
Subindustry
Rank
Percentile
Cochlear Exits (9)
Cochlear’s most recent exit was on 01-Feb-2025 from Epiminder. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Epiminder | 01-Feb-2025 | Completed |
|
||
| Epiminder | 15-Mar-2022 | Completed |
|
||
| Epiminder | 23-Sep-2020 | Completed |
|
||
| Nyxoah | 12-Feb-2020 | Completed |
|
||
| Epiminder | 01-Jan-2019 | Early Stage VC | Completed |
|
Cochlear Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sycle (Business/Productivity Software) | Lone Tree, CO | 2001 | |
| Oticon Medical (Cochlear Implant Business) | Vallauris, France |
Cochlear FAQs
-
When was Cochlear founded?
Cochlear was founded in 1981.
-
Where is Cochlear headquartered?
Cochlear is headquartered in Sydney, Australia.
-
What is the size of Cochlear?
Cochlear has 4,500 total employees.
-
What industry is Cochlear in?
Cochlear’s primary industry is Surgical Devices.
-
Is Cochlear a private or public company?
Cochlear is a Public company.
-
What is Cochlear’s stock symbol?
The ticker symbol for Cochlear is COH.
-
What is the current stock price of Cochlear?
As of 13-Nov-2026 the stock price of Cochlear is $103.03.
-
What is the current market cap of Cochlear?
The current market capitalization of Cochlear is $6.74B.
-
What is Cochlear’s current revenue?
The trailing twelve month revenue for Cochlear is $1.59B.
-
Who are Cochlear’s competitors?
Demant, Boston Scientific, Medtronic, Zimmer Biomet Holdings, and Globus Medical are some of the 11 competitors of Cochlear.
-
What is Cochlear’s annual earnings per share (EPS)?
Cochlear’s EPS for 12 months was $1.53.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process